{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:54:35Z","timestamp":1787072075501,"version":"build-2736575974"},"reference-count":70,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The expansion of neoadjuvant immune checkpoint blockade, chemoimmunotherapy, and targeted therapies in oncogene-driven tumors is reshaping the management of resectable non-small cell lung cancer (NSCLC). Major pathologic response (MPR) and pathologic complete response (pCR), defined respectively as 10% or less residual viable tumor (RVT) within the primary tumor bed and the complete absence of viable tumor in both the resected primary tumor and sampled regional lymph nodes, have become widely adopted early efficacy endpoints. Both are consistently associated with favorable survival outcomes at the patient level, although their validity as trial-level surrogates for long-term outcomes remains incompletely established. Accurate pathologic response assessment requires rigorous standardization of gross specimen handling, tumor bed sampling, and microscopic quantification of viable tumor, necrosis, and stroma. International recommendations have improved methodological harmonization, and reproducibility studies have demonstrated good interobserver agreement when standardized protocols are applied. Increasing evidence also indicates that RVT behaves as a continuous prognostic variable and that integration of primary-tumor and nodal response may improve postoperative risk stratification. Beyond quantification of RVT alone, additional histologic characteristics of the residual tumor, together with stromal and immune therapy-related features, may provide complementary prognostic information. Digital pathology and artificial intelligence may support more reproducible quantitative assessment, whereas circulating tumor DNA-based molecular residual disease evaluation may capture systemic risk not represented by the resection specimen. These emerging approaches remain investigational and require prospective validation. This review critically examines the methodological standardization, biological interpretation, and prognostic validation of pathologic response in resectable NSCLC, and discusses future strategies integrating histopathologic, digital, and molecular variables into post-neoadjuvant risk assessment.<\/jats:p>","DOI":"10.3390\/cancers18162676","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:12:11Z","timestamp":1787069531000},"page":"2676","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Standardizing pCR\/MPR Assessment in NSCLC After Neoadjuvant Therapy: Challenges and Perspectives"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-3193","authenticated-orcid":false,"given":"Andrea","family":"Ascione","sequence":"first","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-298X","authenticated-orcid":false,"given":"Flavia","family":"Adotti","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6327-0786","authenticated-orcid":false,"given":"Luigi","family":"Vittori","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Chiappetta","sequence":"additional","affiliation":[{"name":"Pathology Unit of Policlinico Umberto I, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7066-7896","authenticated-orcid":false,"given":"Paolo","family":"Graziano","sequence":"additional","affiliation":[{"name":"Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"ref_2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"NSCLC Meta-analysis Collaborative Group (2014). Preoperative chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual participant data. Lancet, 383, 1561\u20131571.","DOI":"10.1016\/S0140-6736(13)62159-5"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF01192200","article-title":"Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment","volume":"123","author":"Junker","year":"1997","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO-25-00883","article-title":"Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer","volume":"43","author":"He","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative Pembrolizumab for Early-Stage Non\u2013Small-Cell Lung Cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: Proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","volume":"7","author":"Pataer","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"pkae021","DOI":"10.1093\/jncics\/pkae021","article-title":"Pathological response in resectable non\u2013small cell lung cancer: A systematic literature review and meta-analysis","volume":"8","author":"Waser","year":"2024","journal-title":"JNCI Cancer Spectr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: A proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jtho.2024.03.010","article-title":"Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC","volume":"19","author":"Hines","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6603075","article-title":"Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study","volume":"94","author":"Betticher","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"110732","DOI":"10.1016\/j.ejrad.2023.110732","article-title":"Neoadjuvant immune-checkpoint inhibitors in lung cancer\u2014A primer for radiologists","volume":"161","author":"Kifjak","year":"2023","journal-title":"Eur. J. Radiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non\u2013Small Cell Lung Cancer: A Retrospective Analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Petrella, F., Cara, A., Cassina, E.M., Degiovanni, S., Libretti, L., Lo Torto, S., Pirondini, E., Raveglia, F., Spinelli, F., and Tuoro, A. (2025). Perioperative Strategies in Resectable Non-Squamous Non-Small Cell Lung Cancer with EGFR Mutations and ALK Rearrangement. Cancers, 17.","DOI":"10.3390\/cancers17111844"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1200\/JCO.2025.43.16_suppl.8015","article-title":"Alectinib as Neoadjuvant Treatment in Potentially Resectable Stage III ALK-Positive NSCLC: Final Analysis of ALNEO Phase II Trial (GOIRC-01-2020-ML42316)","volume":"43","author":"Leonetti","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/PAP.0000000000000441","article-title":"Pathology of Surgically Resected Lung Cancers Following Neoadjuvant Therapy","volume":"31","author":"Berezowska","year":"2024","journal-title":"Adv. Anat. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.5858\/arpa.2024-0203-RA","article-title":"Neoadjuvant Therapy and Lung Cancer: Role of Pathologists","volume":"149","author":"Dacic","year":"2025","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.21037\/tlcr-2025-584","article-title":"A narrative review of pathologic response in non-small cell lung cancer: Challenges, implications, and future directions","volume":"14","author":"Li","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.path.2023.11.010","article-title":"Pathologic Response Evaluation in Neoadjuvant-Treated Lung Cancer","volume":"17","author":"Dacic","year":"2024","journal-title":"Surg. Pathol. Clin."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/JTO.0b013e3182774108","article-title":"Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non-Small Cell Lung Cancer after Neoadjuvant Chemotherapy","volume":"8","author":"William","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jtho.2023.07.017","article-title":"International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy","volume":"18","author":"Dacic","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2559.1998.00453.x","article-title":"Partial regression in primary carcinoma of the lung: Does it occur?","volume":"33","author":"Kerr","year":"1998","journal-title":"Histopathology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2021.02.014","article-title":"Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment","volume":"154","author":"Weissferdt","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_32","first-page":"100310","article-title":"Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice","volume":"3","author":"Saqi","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/PAP.0000000000000292","article-title":"Major Pathologic Response in Patients Treated for Non\u2013small Cell Carcinoma of the Lung: Is There a Magic Number in the Histologic Sections to Be Evaluated?","volume":"28","author":"Oramas","year":"2021","journal-title":"Adv. Anat. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"100353","DOI":"10.1016\/j.modpat.2023.100353","article-title":"Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy","volume":"37","author":"Weissferdt","year":"2024","journal-title":"Mod. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/JTO.0b013e31824c7d92","article-title":"Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early-Stage Non-Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized Trials","volume":"7","author":"Mouillet","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1378\/chest.120.5.1584","article-title":"Grading of tumor regression in non-small cell lung cancer: Morphology and prognosis","volume":"120","author":"Junker","year":"2001","journal-title":"Chest"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jtho.2018.11.017","article-title":"Pathologic assessment after neoadjuvant chemotherapy for non-small cell lung cancer: Importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma","volume":"14","author":"Qu","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4143\/crt.2024.670","article-title":"Histological Assessment and Interobserver Agreement in Major Pathologic Response for Non\u2013Small Cell Lung Cancer with Neoadjuvant Therapy","volume":"57","author":"Kim","year":"2025","journal-title":"Cancer Res. Treat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"152268","DOI":"10.1016\/j.anndiagpath.2024.152268","article-title":"Comparison of different criteria for estimating major pathological response in resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy","volume":"69","author":"Sun","year":"2024","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cllc.2019.11.003","article-title":"Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy","volume":"21","author":"Weissferdt","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/JTO.0b013e3181c0a1f8","article-title":"A Novel Histopathological Evaluation Method Predicting the Outcome of Non-small Cell Lung Cancer Treated by Neoadjuvant Therapy: The Prognostic Importance of the Area of Residual Tumor","volume":"5","author":"Yamane","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"107401","DOI":"10.1016\/j.lungcan.2023.107401","article-title":"Evaluation of combined pathological responses in primary tumor and lymph nodes following neoadjuvant chemoimmunotherapy in non-small cell lung cancer","volume":"186","author":"Huang","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Pezzuto, F., Faccioli, E., Mnif, O.E., Maggioni, G., Lunardi, F., Fortarezza, F., Giraudo, C., Schiavon, M., Bonanno, L., and Pasello, G. (2026). Reframing tumor bed evaluation in non-small cell lung cancer: Histopathological challenges and future directions in the era of neoadjuvant immunotherapy. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1716992"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/his.70025","article-title":"Pathologic assessment of resected stage III non-small cell lung cancer after neoadjuvant chemotherapy: Identification of additional prognostic factors","volume":"88","author":"Lunardi","year":"2026","journal-title":"Histopathology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1158\/1078-0432.CCR-19-2379","article-title":"Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade","volume":"26","author":"Stein","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e005531","DOI":"10.1136\/jitc-2022-005531","article-title":"Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer","volume":"10","author":"Sun","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.lungcan.2011.10.020","article-title":"Histopathological and Immunohistochemical Features Associated with Clinical Response to Neoadjuvant Gefitinib Therapy in Early-Stage Non-Small Cell Lung Cancer","volume":"76","author":"Chung","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100007","DOI":"10.1016\/j.xcrm.2020.100007","article-title":"Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR-Mutant Lung Cancer","volume":"1","author":"Roper","year":"2020","journal-title":"Cell Rep. Med."},{"key":"ref_50","first-page":"100420","article-title":"Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy","volume":"3","author":"Pataer","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jtho.2021.03.029","article-title":"Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy","volume":"16","author":"Pataer","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41379-021-00871-1","article-title":"Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer","volume":"34","author":"Liu","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/1759-7714.13903","article-title":"Is major pathologic response sufficient to predict survival in resectable nonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy?","volume":"12","author":"Cai","year":"2021","journal-title":"Thorac. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0169-5002(03)00245-9","article-title":"The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer","volume":"42","author":"Sawabata","year":"2003","journal-title":"Lung Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","article-title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: A re-analysis of meta-analyses of individual patients\u2019 data","volume":"14","author":"Mauguen","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1080\/14737140.2023.2272645","article-title":"Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: A systematic review and meta-analysis","volume":"23","author":"Ostoros","year":"2023","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"104122","DOI":"10.1016\/j.esmoop.2024.104122","article-title":"Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?","volume":"10","author":"Sugiyama","year":"2025","journal-title":"ESMO Open"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-023-02371-y","article-title":"Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance","volume":"29","author":"Chu","year":"2023","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7329","DOI":"10.2147\/OTT.S218321","article-title":"Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC","volume":"12","author":"Yi","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.21037\/jtd-22-1685","article-title":"Efficacy and safety of immunoradiotherapy for advanced non-small cell lung cancer: A retrospective comparative cohort study","volume":"15","author":"Gao","year":"2023","journal-title":"J. Thorac. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lee, K.C., Shin, H., Ohn, J., Park, J.H., Park, S., Park, I.K., Kang, C.H., Kim, Y.T., Choi, H., and Koh, J. (2026). Diagnostic accuracy of an AI-based pathologic response assessment in locally advanced non-small cell lung cancer after neoadjuvant chemo-immunotherapy. BMC Cancer, 26.","DOI":"10.1186\/s12885-026-15885-8"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"14144","DOI":"10.1038\/s41598-026-44633-y","article-title":"Estimating major pathological response in non-small cell lung cancer patients with post-neoadjuvant therapy using MMT-net","volume":"16","author":"Yang","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-025-03592-4","article-title":"The role of artificial intelligence-based foundation models and \u201ccopilots\u201d in cancer pathology: Potential and challenges","volume":"45","author":"Cheng","year":"2026","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jtho.2023.12.010","article-title":"Artificial Intelligence\u2013Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study","volume":"19","author":"Dacic","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.21.02660","article-title":"Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)","volume":"40","author":"Provencio","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/1078-0432.CCR-14-1190","article-title":"Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility","volume":"21","author":"Ignatiadis","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.21037\/atm-21-525","article-title":"Liquid Biopsy in Esophageal Cancer: A Case Report of False-Positive Circulating Tumor DNA Detection Due to Clonal Hematopoiesis","volume":"9","author":"Spoor","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"103551","DOI":"10.1016\/j.eclinm.2025.103551","article-title":"AI-derived longitudinal and multi-dimensional CT classifier for non-small cell lung cancer to optimize neoadjuvant chemoimmunotherapy decision: A multicentre retrospective study","volume":"89","author":"Ye","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jtcvs.2024.05.006","article-title":"Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non\u2013small cell lung cancer","volume":"169","author":"Xu","year":"2025","journal-title":"J. Thorac. Cardiovasc. Surg."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2676\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:18:21Z","timestamp":1787069901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":70,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162676"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162676","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}